Fluvoxamine for the treatment of COVID-19-Reference-Cited by-同舟云学术

Fluvoxamine for the treatment of COVID-19

Published:2022-09-14 Issue:9 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Nyirenda John LZ¹²,Sofroniou Mario³⁴⁵,Toews Ingrid¹,Mikolajewska Agata⁶⁷,Lehane Cornelius⁸,Monsef Ina⁹,Abu-taha Aesha³,Maun Andy³,Stegemann Miriam⁷,Schmucker Christine¹

Affiliation:

1. Institute for Evidence in Medicine; Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Freiburg Germany

2. Public Health Department, Faculty of Applied Sciences; University of Livingstonia; Mzuzu Malawi

3. Institute of General Practice/Family Medicine; Faculty of Medicine, Medical Center - University of Freiburg; Freiburg Germany

4. NHS South West England; National Health Service; England UK

5. Fellow, Royal College of General Practitioners; FRCGP; London UK

6. Centre for Biological Threats and Special Pathogens (ZBS), Strategy and Incident Response (ZBS7), Clinical Management and Infection Control (ZBS7.1); Robert Koch Institute; Berlin Germany

7. Department of Infectious Diseases and Respiratory Medicine; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Berlin Germany

8. Department of Anesthesiology; University Heart Center Freiburg, Bad Krozingen; Freiburg Germany

9. Faculty of Medicine and University Hospital Cologne, University of Cologne; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cochrane Haematology; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference101 articles.

1. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial;Lenze;Journal of the American Medical Association,2020

2. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection clinicaltrials.gov/ct2/show/NCT04342663

3. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms www.clinicaltrials.gov/ct2/show/NCT04727424

4. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial;Reis;Lancet Global Health,2021

5. Fluvoxamine in the treatment of patients with COVID-19;Assanovich;Psychiatry, Psychotherapy and Clinical Psychology,2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for poor COVID-19 outcomes in patients with psychiatric disorders;Brain, Behavior, and Immunity;2023-11

2. Impact of some antiviral drugs on health care utilization for patients with COVID-19: a systematic review and meta-analysis;Expert Review of Anti-infective Therapy;2023-09-02

3. COVID-19 mortality among selective serotonin reuptake inhibitor users—results from a nationwide cohort;Clinical Microbiology and Infection;2023-08

4. Prediction of CYP-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Modeling: A Case Study of Salbutamol and Fluvoxamine;Pharmaceutics;2023-05-24

5. Pharmacokinetics and bioequivalence studies of fluvoxamine maleate tablets in healthy Chinese subjects;Biomedical Chromatography;2023-03-27